| Author/Editor | Šebeštjen, Miran | |
| Title | Novi dejavniki tveganja za aterosklerozo: pomen in možnosti zdravljenja | |
| Type | monografija | |
| Place | Ljubljana | |
| Publisher | Univerza v Ljubljani, Medicinska fakulteta | |
| Publication year | 2005 | |
| Volume | str. 117 | |
| Language | slo | |
| Abstract | In the initiation and progression of the atherosclerotic process not only classical risk factors as hyperlipoproteinemia, diabetes mellitus, hypertension, obesity and smoking are involved, but also novel risk factors, among them the distwbances in coagulation and fibrinolytic system, inflammatory parameters, homocysteine and mostly endothelial dysfunction. The endothelium is able to sense changes in hemodynamic forces and responds to physical and chemical stimuIi by symhesis or release of a variety of vasoactive and thromboregulatory molecules, growth factors and inflammatory mediators, therefore endothelial function could reflect the influence of various cardiovascular risk factors. The aim of our studies was to fmd out whether lipolytic drugs with different lipolytic effects differ in their effects on new cardiovascular risk factors, and whether among these new risk factors endothelial function could potentially serve as a diagnostic tool that could distinguish patients that are at higher tisk of future coronary events despite similar risk factor profiles. In the first two studies we followed 38 males with combined hyperlipidemia before and after 12 weeks treatment with cerivastatin or fenofibrate. We determinated endothelial dependent and independent dilation of brachial artery and serum levels of blood lipids and lipoproteins, parameters of coagulation and fibrinolysis, homocysteine, proinflammatory cytokines and C-reactive protein. Beside measurements as in the first two studies, we performed also ultrasound measurements of carotid artery intima-media thickness in the third smdy in 72 patients with combined hyperlipidemia. In the forth study we examined changes of arterial vasoreactivity in 14 patients with hypercholesterolemia following 12 weeks treatment with simvastatin or pravastatin. (Abstract truncated at 2000 characters). | |
| Descriptors | ATHEROSCLEROSIS HYPERLIPIDEMIA ANTILIPEMIC AGENTS BRACHIAL ARTERY PROCETOFEN RISK FACTORS VASODILATION C-REACTIVE PROTEIN HOMOCYSTEINE INTERLEUKIN-6 TUMOR NECROSIS FACTOR LIPOPROTEINS, HDL CHOLESTEROL LIPOPROTEINS, LDL CHOLESTEROL CREATININE ALTEPLASE PLASMINOGEN ACTIVATOR INHIBITOR 1 CAROTID ARTERIES HYPERCHOLESTEROLEMIA |